Catalent has agreed to acquire Juniper Pharmaceuticals, along with its Juniper Pharma Services division based in Nottingham, UK.

Catalent will initiate a tender offer to purchase all of the shares of Juniper for $11.50 a share, as part of the acquisition.

Based in the US, Catalent is a drug delivery technology and development solutions provider, while Juniper Pharmaceuticals, also based in the US, is a specialist pharmaceutical company engaged in the development of therapeutics for unmet medical needs.

Juniper’s acquisition will enable the acquirer company to strengthen its formulation development and clinical-scale oral dose manufacturing capabilities.

Rothschild & Co has been appointed as financial adviser, while Goodwin Procter is acting as legal counsel to Juniper for the transaction.

CVC Capital Partners has entered an agreement to purchase 51.8% interest in Recordati for €3bn ($3.4bn) or €28 ($32) a share.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CVC will pay €2.3bn ($2.6bn) in cash and the remaining €750m ($867m) in the form of long-term debt securities, under the agreement.

“CVC Capital Partners has entered an agreement to purchase 51.8% interest in Recordati for €3bn ($3.4bn) or €28 ($32) a share.”

CVC is a private equity firm based in Luxembourg, while Recordati is an Italian pharmaceutical group engaged in pharmaceutical research, development and marketing.

The transaction will enable Recordati to expand its footprint in Italy and continue to operate as an independent company.

The acquisition is expected to be closed in the fourth quarter of 2018, subject to regulatory approvals.

Bain Capital Private Equity has entered an agreement to purchase DSM Sinochem Pharmaceuticals (DSP) from Royal DSM and Sinochem Group.

DSM will be paid approximately €250m ($289m) for its stake, which does not include earn-out and transaction costs.

Rothschild & Co has been appointed as financial adviser to both DSM and Sinochem for the transaction.

The transaction is expected to be closed in the fourth quarter of 2018, subject to customary closing conditions and other regulatory approvals.

Based in the US, Bain Capital is a private equity firm, while DSM Sinochem is an antibiotics and anti-fungals producer based in Netherlands.

Also based in the Netherlands, Royal DSM is a global science company operating in the fields of health and nutrition, while Sinochem Group is a Chinese firm engaged in the production and marketing of chemicals and fertilisers.